Advances in Coronary Artery Disease: Moving Beyond Antiplatelet Therapy.

Slides:

Advertisements

Similar presentations

Luigi Oltrona Visconti Divisione di Cardiologia IRCCS Fondazione Policlinico S. Matteo Pavia Sindromi coronariche acute nei pazienti con fibrillazione.

Advertisements

WarfarinApixaban Primary outcome: major/clinically relevant bleeding (through 6 months) Secondary objective: Death, MI, stroke, stent thrombosis Randomize.

How to Navigate the New Oral Anticoagulants and Deal With Triple Therapy Dr. Morteza Safi Professor of interventional cardiology Cardiovascular Research.

The patient with atrial fibrillation who needs PCI

Denise Sutter, PharmD, BCPS

When should aspirin be dropped from triple therapy?

Addressing the Challenges in Primary and Secondary Stroke Prevention

Polypharmacy Anticoagulation: AF meets PCI

Anticoagulant Safety Remains a Problem Emergency Hospitalizations for Adverse Drug Events.

(p < for group 1 or 2 vs. group 3)

Preventing Thrombotic Complications in ACS: State of the Art

Oral Anticoagulation and Preventing Stent Thrombosis

Duration of Dual Antiplatelet Therapy Post-ACS: Lessons From Clinical Trials.

New Concepts in Peripheral Artery Disease: Emerging Role of Antithrombotics.

Atrial Fibrillation and PCI

Anticoagulants in Interventional Cardiology:

Updates in Anticoagulation: What Did We Learn From ESC 2017?

NOACs, AF, and PCI: What Do the Latest Data Suggest?

Achieving Long-Term Protection Post-MI

When Is Adding Aspirin to NOACs Worth the Risk?

Barriers to Oral Anticoagulant Use for Stroke Prevention in AF

Thrombosis, Cancer, and NOACs

Access to NOAC Therapy:

Emergency Management of NOAC Bleeding

A New Era for NOACs:.

POWER IN NUMBERS: REVISITING EFFICACY & SAFETY OF NOACS IN AF

Unmet Needs in the Secondary Prevention in ACS

Anticoagulation Highlights From the American Heart Association Meeting 2017.

Duration of Dual Antiplatelet Therapy Post-ACS: Lessons from Clinical Trials.

New Perspectives in AF and PCI: Implications for the Practicing Physician.

Antithrombotics and PAD: A New Paradigm in Practice

New Perspectives in CAD and PAD: Weighing the Latest Evidence

Surveying the Safety of NOACs in the Real World

Selecting NOACs for High-Risk Patients

Learning Objectives PLATO Primary Efficacy End Point CV Death, MI, or Stroke.

Treatment Options to Consider

Real-World Safety of NOACs: What Do We Know Today?

NOACS: Emerging data in ACS/IHD

AF and PCI in Practice.

Access to NOAC Therapy:

Antithrombotic Protection in CAD and HF

TAVR and the Risk of Thrombosis

A Better Solution For Cancer Patients With VTE?

Risk Stratification in CAD and PAD

Oral Anticoagulation in AF

Real-World Evidence in VTE

Dos and Don’ts for High-Risk Elderly Patients With AF

Treatment of Thromboembolic Disease The Need for Multiple Perspectives

DOACs and Urgent Bleeding

Anticoagulation and Thrombosis Management

Duration of Dual Antiplatelet Therapy Post-ACS: Lessons from Clinical Trials.

Trials and Tribulations in VTE: How Do Real-World Data Fit In?

Factor Xa Inhibitors in PAD

CAD/PAD in Primary Care

What You Didn't Know About AF and Renal Dysfunction

Cancer-Associated Thrombosis

CAD and HF Often Coexist

A Case Challenge.

Antithrombotic Therapy in Vascular Protection: From CAD to HF

Updates in Anticoagulation: Key Sessions at ESC 2017

Antithrombotics in Arterial Disease: Focus on Coronary Disease

The Challenge of AF and PCI: Practical Strategies to Improve Outcomes

Factor Xa Inhibitors in Coronary Artery Disease

NOACs and Reversal Agents

Antithrombotic strategies in patients on long-term oral anticoagulation therapy undergoing percutaneous coronary intervention. ACS: acute coronary syndrome;

Pamela E. Scott et al. JACC 2018;71:

Antithrombotic Therapy in AF Patients Undergoing PCI

What's New in NOACs in AF?.

Can the Dual vs Triple Therapy Controversy in Patients With AF Undergoing PCI Be Put to Rest?

Presentation transcript:

Advances in Coronary Artery Disease: Moving Beyond Antiplatelet Therapy

Program Goals

Antiplatelet Therapy for CAD: Established Therapy

Anticoagulant Therapy for CAD Warfarin -- WARIS-2

Anticoagulant Therapy With NOACs for CAD Apixaban -- APPRAISE-2

Rivaroxaban: ATLAS ACS 2—TIMI 51

ATLAS ACS 2—TIMI 51 Primary Efficacy Outcome

ATLAS ACS 2—TIMI 51 Bleeding Outcome

Dabigatran: RE-DEEM Primary and Secondary Outcome

ATLAS ACS 2—TIMI 51 Mortality and Stent Thrombosis

NOACs Plus Antiplatelet Agents: Lessons Learned

WOEST Dual vs Triple Therapy

WOEST Primary and Secondary Outcome

PIONEER AF-PCI Trial Design

PIONEER AF-PCI Clinically Significant Bleeding

PIONEER AF-PCI Substudy First Recurrent Hospitalization Due to Bleeding

Ongoing NOAC Trials in Patients With AF-PCI

COMPASS Trial Design

COMPASS Trial Design (cont)

COMPASS Inclusion/Exclusion Criteria

Targets of Antithrombotic Agents

COMPASS MIND

Concluding Remarks

Abbreviations

Abbreviations (cont)